WARRIOR Trial: Outcomes to Reduce Events in N...

What exactly is incidental coronary artery calcification, and what does it mean when artificial intelligence identifies these calcifications? Incidental coronary artery calcification refers to calcium deposits in the coronary arteries that are detected on imaging studies performe ...  Show more

The VESALIUS‑CV trial demonstrated that adding the PCSK9 inhibitor evolocumab to optimized lipid‑lowering therapy significantly reduced the risk of first major cardiovascular events by 25% in high‑risk adults without prior heart attack or stroke and cut the risk of first heart at ...  Show more

In this episode of Audible Bleeding, Jamila, Anh, and Naveed discuss the LifeBTK Trial with Principal Investigator Dr. Brian DeRubertis, where we discuss the new Abbott Esprit everolimus-eluting resorbable scaffold for the below-knee popliteal space. Guest: Dr. DeRubertis, is the ...  Show more

How much do beta blockers help after a heart attack, even when the heart’s pumping well? In this episode, we revisit the origins of beta blockers in post-MI care, examine how evidence evolved, and explore the REDUCE-AMI trial, which questions whether beta blockers are still neede ...  Show more

In this episode of the PTJ Podcast, Editor-in-Chief Steven George, PT, PhD, FAPTA, talks with Alexander Garbin, PT, DPT, PhD, and Jennifer Stevens-Lapsley, PT, PhD, FAPTA, about their recently published companion papers, which evaluated the effectiveness of a progressive multi ...

In this episode, Dr. Harlan Krumholz introduces the September 16, 2025 issue of JACC, which features studies that challenge conventional clinical thinking, including a detailed ECMO physiology study showing that higher ECMO flow does not uniformly raise pulmonary capillary wedge ...  Show more